CA-SOLIDIGM
26.4.2022 18:02:05 CEST | Business Wire | Press release
Today Solidigm is expanding its performance-optimized D7 Product Series with new solid-state storage drives (SSDs) — the D7-P5520 and the D7-P5620 — for data center and enterprise use. These drives are optimized for real-world compute and storage server workloads and are available in an extended range of form factors and capacities. They offer accelerated performance and reduced total cost of ownership (TCO) by enabling a smaller storage footprint and lower power consumption.
The D7-P5520 (designed for read-intensive and light mixed workloads), and the D7-P5620 (designed for mixed workloads), are the first family of products being introduced by Solidigm, which launched as a standalone company in December 2021.
The D7 Series comprises the industry’s most advanced PCIe 4.0 SSD family of products given their capacity offerings, breadth of form factors and optimized performance capabilities. These SSDs are optimized for real-world workloads and reflect insights gained from deep technical engagements with leading cloud service providers, OEMs, and storage innovators. Designed and tested with zero tolerance for data errors, consistently durable IOPS and QoS, and with near-zero lifetime performance degradation, they can be deployed with the utmost confidence.
“Our deep technical engagements spanning all industry segments give us unique customer insights to optimize our products,” said David Dixon, SVP and General Manager, Data Center, Solidigm. “The D7-P5520 and the D7-P5620 are the culmination of these insights and of multiple 3D NAND and PCIe 4.0 generations, which enable us to deliver a best-in-class offering and a new paradigm in solid-state storage.”
ByteDance partnered with Solidigm early in product development and qualified the D7-P5520 with outstanding results before live deployment in March 2022. The drives are delivering a breadth of capacity and performance improvements over prior generations, which has allowed them to boost performance by 33% with dramatic TCO improvement for database and cloud software-defined storage. The D7-P5520 will also be used in ByteDance’s public cloud services platform Volcano Engine.
Key Benefits:
-
Accelerated performance
across a range of workloads:
- D7-P5520 : up to 42% higher 4K Random Reads, 17% higher 4K Random Writes, with up to 43% better latency generation to generation. It also delivers up to 40% better read responsiveness in the presence of write pressure as compared to the competition, a key consideration for real-world workloads.
- D7-P5620: up to 56% 4K higher Random Reads, and up to 53% higher Random Writes, with up to 29% better latency generation to generation.
- Total cost of ownership (TCO) can be reduced through the combination of higher performance and expanded capacities. For example, OEMs designing for a 10M IOPS 2U server can reduce the storage footprint up to 27% while reducing power consumption up to 20% generation over generation.
- The D7 Series can be used in a wide array of storage configurations , including 1U and 2U tiered and monolithic configurations in compute and storage servers. The drives are available with extended capacity ranges and in multiple form factors, including E1.L and multiple E1.S offerings.
- Qualifications can be streamlined since Solidigm’s D7-P5520 and D7-P5620 family of products share common NAND, firmware, and controllers across SKUs.
- Quality and reliability are designed into these drives. For example, extra firmware checks are added to validate that data was saved accurately in the event of power loss. Additionally, the drives have been rigorously tested beyond industry specifications and common industry practices.
Visit solidigm.com for more information on the D7-P5620, the D7-P5520, and the full D7 Series, tuned for real-world mixed and performance-sensitive workloads. You can also learn more during a live webinar on June 15, 2022, 9 a.m. PT. Information and registration .
ABOUT SOLIDIGM
Solidigm is a leading global provider of innovative NAND flash memory solutions. Solidigm technology unlocks data’s unlimited potential for customers, enabling them to fuel human advancement. Our origins reflect Intel’s longstanding innovation in memory products and SK hynix’s international leadership and scale in the semiconductor industry. Solidigm became a standalone U.S. subsidiary under SK hynix in December 2021. Headquartered in San Jose, CA, Solidigm is powered by the inventiveness of close to 2,000 employees in 20 locations around the world. For more information, please visit solidigm.com and follow us on Twitter at @Solidigm and on LinkedIn .
All products, computer systems, dates, and figures specified are preliminary based on current expectations, and are subject to change without notice.
Tests document performance of components on a particular test, in specific systems. Differences in hardware, software, or configuration will affect actual performance. Consult other sources of information to evaluate performance as you consider your purchase.
Performance results are based on testing as of dates shown in the configurations and may not reflect all publicly available updates. See configuration disclosure for details. No product or component can be absolutely secure.
Solidigm optimizations, for Solidigm compilers or other products, may not optimize to the same degree for non-Solidigm products.
Solidigm technologies may require enabled hardware, software, or service activation.
Your costs and results may vary.
© Solidigm. “Solidigm” is a trademark of SK hynix NAND Product Solutions Corp. “Intel” is a registered trademark of Intel Corporation. Other names and brands may be claimed as the property of others.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005470/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
